Modality
mAb
MOA
HPK1i
Target
BCMA
Pathway
RNA Splicing
Ewing SarcomaFLDLBCL
Development Pipeline
Preclinical
~Sep 2022
→ ~Dec 2023
Phase 1
Mar 2024
→ Sep 2030
Phase 1Current
NCT06952941
71 pts·DLBCL
2025-10→2029-09·Completed
NCT06320111
390 pts·Ewing Sarcoma
2024-03→2030-09·Active
461 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-01-152mo agoEMA Filing· Ewing Sarcoma
2029-09-163.5y awayPh2 Data· DLBCL
2030-09-244.5y awayPh2 Data· Ewing Sarcoma
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Active
P1/2
Complet…
Catalysts
EMA Filing
2026-01-15 · 2mo ago
Ewing Sarcoma
Ph2 Data
2029-09-16 · 3.5y away
DLBCL
Ph2 Data
2030-09-24 · 4.5y away
Ewing Sarcoma
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06952941 | Phase 1/2 | DLBCL | Completed | 71 | LiverFat |
| NCT06320111 | Phase 1/2 | Ewing Sarcoma | Active | 390 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 |